Schöffski, Patrick
George, Suzanne
Heinrich, Michael C.
Zalcberg, John R.
Bauer, Sebastian
Gelderblom, Hans
Serrano, César
Jones, Robin L.
Attia, Steven
D’Amato, Gina
Chi, Ping
Reichardt, Peter
Becker, Claus
Shi, Kelvin
Meade, Julie
Ruiz-Soto, Rodrigo
Blay, Jean-Yves
von Mehren, Margaret
Article History
Received: 25 March 2022
Accepted: 28 November 2022
First Online: 13 December 2022
Declarations
:
: This study was done in accordance with the Declaration of Helsinki and the International Council for Harmonisation Guidelines for Good Clinical Practice. Patients had to provide written, informed consent to participate in this study. The protocol, protocol amendments, and informed-consent documents were approved by the Western Institutional Review Board-Copernicus Group (Puyallup, WA, USA). A local institutional review board or ethics committee at each site approved the protocol, protocol amendments, and informed-consent documents before the start of the study.
: Not applicable.
: PS has received honoraria from Deciphera, Blueprint, and Boehringer Ingelheim; serves in an advisory/consultancy role for Deciphera, Ellipses Pharma, Blueprint, Transgene, Exelixis, Boehringer Ingelheim, Medscape, Guided Clarity, Adaptimmune, Inteillisphere, and Advanced Medical; his institution has received research funding from CoBioRes NV, Eisai, G1 Therapeutics, Novartis, and PharmaMar; and has received travel, accommodations, expenses from Boehringer Ingelheim, and his institution has received them from MSD and Ipsen. SG serves in an advisory/consultancy role for AstraZeneca, Bayer, Blueprint, Daiichi Sankyo, Deciphera, Eli Lilly, and Exelixis; has a leadership role in Alliance Foundation; receives licensing royalties from Wolters Kluwer Health; is a shareholder/stockholder of Abbott Labs and her institution receives research support from Bayer, Blueprint, Deciphera, Novartis, Daiichi Sankyo, Springworks, Merck, Eisai, and Pfizer. MCH serves in a consultancy role for Novartis, Deciphera, Blueprint, Molecular MD, and Novartis; receives royalties from Novartis; receives research funding from Blueprint and Deciphera; had an equity interest in Molecular MD, and has received travel, accommodations, expenses from Blueprint and Deciphera. JZ serves in an advisory/consultancy role for Merck Serono, Targovax, Merck Sharp & Dohme, Halozyme, Lipotek, Specialised Therapeutics, CEND, Deciphera; owns stock in GW Pharmaceuticals, Aimmune, Vertex, Alnylam, Biomarin, Opthea, Amarin, Concert Pharmaceuticals, Frequency Therapeutics, Global Blood Therapeutics, Gilead, Madrigal Pharmaceuticals, Sangamo Biosciences, Acceleron Pharmaceuticals, Zogenix, Myovant Sciences, Orphazyme, Moderna Therapeutics, and TWST; has received honoraria from Specialised Therapeutics, Merck Serono, Targovax, Halozyme, Gilead Sciences, and Deciphera; and his institution has received research funding from Merck Serono, Bristol-Myers Squibb, AstraZeneca, Pfizer, IQvia, Mylan, Ipsen, Eisai, Medtronic, and MSD Oncology; and has received travel, accommodations, expenses from Merck Serano, AstraZeneca, and Merck Sharp & Dohme. SB serves in an advisory/consultancy role for Blueprint, Bayer, Eli Lilly, Deciphera, Nanobiotix, Daiichi Sankyo, Exelixis, Janssen-Cilag, ADC Therapeutics, Mundipharma, and GSK; has received honoraria from Novartis, Pfizer, Bayer, PharmaMar, and GlaxoSmithKline; has received research funding from Blueprint, and Novartis, and his institution has received research funding from Incyte. HG institution has received research funding from Daiichi Sankyo, Five Prime, Novartis, Deciphera, Eli Lilly, Roche, Eisai, Debio, Boehringer Ingelheim Ltd, Pfizer, Amgen, and TEVA. CS serves in an advisory/consultancy role for Deciphera, Blueprint, and Immunicum; is a member of the speaker’s bureau for Blueprint, and his institution has received research funding from Pfizer, and Karyopharm Therapeutics. RLJ has received honoraria and serves in an advisory role for Adapimmune Therapeutics Plc, Athenex Inc, Bayer, Blueprint, Clinigen Group Plc, Daiichi Sankyo, Deciphera, Eisai, Epizyme, Immunedesign, Eli Lilly, Merck, PharmaMar, UpToDate; and serves in an advisory role for Boehringer Ingelheim Ltd and Tracon Pharma; and has received research funding from MSD. SA has received research funding from Desmoid Tumor Research Foundation; and his institution has received research funding from AB Science, TRACON Pharma, Bayer, Novartis, Eli Lilly, Immune Design, Karyopharm Therapeutics, Epizyme, Blueprint, Genmab, CBA Pharma, Merck, Philogen, Gradalis, Deciphera, Takeda, Incyte, Springworks, Adaptimmune, Advenchen Laboratories, Barvarian Nordic, BTG, GlaxoSmithKline, and FORMA Therapeutics. GD serves in an advisory/consultancy role for Deciphera. PC serves in an advisory role for Deciphera, Exelixis, Zailab; has received grant funding from Deciphera, Exelixis, Novartis, and Array; and has licensing royalties and owns stock in ORIC. PR serves in an advisory/consultancy role for Clinigen Group, Roche, Bayer, Deciphera, MSD, and Bristol-Myers Squibb; has received honoraria from Novartis, Pfizer, PharmaMar, Eli Lilly, and Amgen; and his institution has received research funding from Novartis. CB is employed by Deciphera. KS is employed by Deciphera, and owns stock in Alnylam, Immunogen, Karyopharm, Deciphera, Spectrum, AstraZeneca and Alberio. JM was employed by Deciphera at the time this analysis was conducted and owns stock in Deciphera. RR-S is employed by Deciphera, and owns stock in Deciphera, and Immunogen. J-YB serves in an advisory/consultancy role and has received honoraria from Novartis, Bayer, Pfizer, Deciphera, PharmaMar, Ignyta, and Roche. MvM serves in an advisory/consultancy role for Deciphera, Blueprint, Exelexis, and GSK; has received travel/accommodation expenses from Deciphera and NCCN; and her institution has received funding from Arog, ASCO, Blueprint, Deciphera, Garadalis, GenMab, Novartis, and Solarius.